Integrin inhibitor suppresses bevacizumab-induced glioma invasion

Translational Oncology

Volumn 7, Issue 2, 2014, Pages 292-302.e1

  Ishida, Joji ^a   Onishi, Manabu ^a   Kurozumi, Kazuhiko ^a   Ichikawa, Tomotsugu ^a   Fujii, Kentaro ^a   Shimazu, Yosuke ^a   Oka, Tetsuo ^a   Date, Isao ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAVBETA5 INTEGRIN; B RAF KINASE; BEVACIZUMAB; CAVEOLIN 3; CD40 ANTIGEN; CILENGITIDE; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; INTEGRIN; INTERLEUKIN 2 RECEPTOR BETA; LAMININ; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PROTEIN KINASE P60; SCATTER FACTOR RECEPTOR; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL ADHESION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSMISSION ELECTRON MICROSCOPY; TUMOR INVASION; UPREGULATION;

EID: 84902517667     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1016/j.tranon.2014.02.016     Document Type: Article

References (31)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, and Bogdahn U, et al (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352, 987-996.
2. Bokstein F, Shpigel S, and Blumenthal DT (2008). Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer 112, 2267-2273.
3. Vredenburgh JJ, Desjardins A, Herndon 2nd JE, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, and Sampson J, et al (2007). Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25, 4722-4729.
4. Dvorak HF (2002). Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20, 4368-4380.
5. Desjardins A, Reardon DA, Herndon 2nd JE, Marcello J, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, and Bailey L, et al (2008). Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 14, 7068-7073.
6. Piao Y, Liang J, Holmes L, Zurita AJ, Henry V, Heymach JV, and de Groot JF (2012). Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Neuro Oncol 14, 1379-1392.
7. Hynes RO (2002). Integrins: bidirectional, allosteric signaling machines. Cell 110, 673-687.
8. Maubant S, Saint-Dizier D, Boutillon M, Perron-Sierra F, Casara PJ, Hickman JA, Tucker GC, and Van Obberghen-Schilling E (2006). Blockade of αvβ3 and αvβ5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells. Blood 108, 3035-3044.
9. Onishi M, Kurozumi K, Ichikawa T, Michiue H, Fujii K, Ishida J, Shimazu Y, Chiocca EA, Kaur B, and Date I (2013). Gene expression profiling of the antiglioma effect of Cilengitide. Springerplus 2, 160.
10. Oliveira-Ferrer L, Hauschild J, Fiedler W, Bokemeyer C, Nippgen J, Celik I, and Schuch G (2008). Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway. J Exp Clin Cancer Res 27, 86.
11. Kurozumi K, Ichikawa T, Onishi M, Fujii K, and Date I (2012). Cilengitide treatment for malignant glioma: current status and future direction. Neurol Med Chir (Tokyo) 52, 539-547.
12. Kambara H, Okano H, Chiocca EA, and Saeki Y (2005). An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res 65, 2832-2839.
13. Onishi M, Ichikawa T, Kurozumi K, Fujii K, Yoshida K, Inoue S, Michiue H, Chiocca EA, Kaur B, and Date I (2013). Bimodal anti-glioma mechanisms of cilengitide demonstrated by novel invasive glioma models. Neuropathology 33, 162-174.
14. Kurozumi K, Hardcastle J, Thakur R, Yang M, Christoforidis G, Fulci G, Hochberg FH, Weissleder R, Carson W, and Chiocca EA, et al (2007). Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst 99, 1768-1781.
15. Hawkins BT and Davis TP (2005). The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 57, 173-185.
16. Weller M and Yung WK (2013). Angiogenesis inhibition for glioblastoma at the edge: beyond AVAGlio and RTOG 0825. Neuro Oncol 15, 971.
17. de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, and Conrad CA (2010). Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol 12, 233-242.
18. DeLay M, Jahangiri A, Carbonell WS, Hu YL, Tsao S, Tom MW, Paquette J, Tokuyasu TA, and Aghi MK (2012). Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy. Clin Cancer Res 18, 2930-2942.
19. Platten M, Wick W, Wild-Bode C, Aulwurm S, Dichgans J, and Weller M (2000). Transforming growth factors β1 (TGF-β1) and TGF-β2 promote glioma cell migration via up-regulation of αVβ3 integrin expression. Biochem Biophys Res Commun 268, 607-611.
20. Deryugina EI and Bourdon MA (1996). Tenascin mediates human glioma cell migration and modulates cell migration on fibronectin. J Cell Sci 109 (Pt 3), 643-652.
21. Fujii K, Kurozumi K, Ichikawa T, Onishi M, Shimazu Y, Ishida J, Chiocca EA, Kaur B, and Date I (2013). The integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus. Cancer Gene Ther 20, 437-444.
22. Inoue S, Ichikawa T, Kurozumi K, Maruo T, Onishi M, Yoshida K, Fujii K, Kambara H, Chiocca EA, and Date I (2011). Novel animal glioma models that separately exhibit two different invasive and angiogenic phenotypes of human glioblastomas. World Neurosurg 78, 670-682.
23. Onishi M, Kurozumi K, Ichikawa T, and Date I (2013). Mechanisms of tumor development and anti-angiogenic therapy in glioblastoma multiforme. Neurol Med Chir (Tokyo) 53, 755-763.
24. Lombardi G, Zustovich F, Farina P, Polo V, Farina M, Puppa AD, Bertorelle R, Gardiman MP, Berti F, and Zagonel V (2012). Cilengitide in bevacizumabrefractory high-grade glioma: two case reports and critical review of the literature. Anticancer Drugs 23, 749-753.
25. Lu KV, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, Meyronet D, Isachenko N, Fouse SD, Phillips JJ, and Cheresh DA, et al (2012). VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/ VEGFR2 complex. Cancer Cell 22, 21-35.
26. Piao Y, Liang J, Holmes L, Henry V, Sulman E, and de Groot JF (2013). Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition. Clin Cancer Res 19, 4392-4403.
27. von Baumgarten L, Brucker D, Tirniceru A, Kienast Y, Grau S, Burgold S, Herms J, and Winkler F (2011). Bevacizumab has differential and dosedependent effects on glioma blood vessels and tumor cells. Clin Cancer Res 17, 6192-6205.
28. Ziu M, Schmidt NO, Cargioli TG, Aboody KS, Black PM, and Carroll RS (2006). Glioma-produced extracellular matrix influences brain tumor tropism of human neural stem cells. J Neurooncol 79, 125-133.
29. Mahesparan R, Read TA, Lund-Johansen M, Skaftnesmo KO, Bjerkvig R, and Engebraaten O (2003). Expression of extracellular matrix components in a highly infiltrative in vivo glioma model. Acta Neuropathol 105, 49-57.
30. Huijbers IJ, Iravani M, Popov S, Robertson D, Al-Sarraj S, Jones C, and Isacke CM (2010). A role for fibrillar collagen deposition and the collagen internalization receptor endo180 in glioma invasion. PLoS One 5, e9808.
31. Silver DJ, Siebzehnrubl FA, Schildts MJ, Yachnis AT, Smith GM, Smith AA, Scheffler B, Reynolds BA, Silver J, and Steindler DA (2013). Chondroitin sulfate proteoglycans potently inhibit invasion and serve as a central organizer of the brain tumor microenvironment. J Neurosci 33, 15603-15617.